Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag Plus Diacerein in ITP
NCT04917679Phase 2Completed
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of diacerein in primary immune thrombocytopenia (ITP), sponsored by Qilu Hospital of Shandong University. Started Sep 2020; status: completed.
02
Drugs
diacerein
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04917679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04917679.